Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10. August 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
13. Juli 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
13. Mai 2021 09:15 ET
|
Vallon Pharmaceuticals Inc.
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...
Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
11. Mai 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...
Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
07. Mai 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:...
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
26. April 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
13. April 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
29. März 2021 08:05 ET
|
Vallon Pharmaceuticals Inc.
- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
03. März 2021 08:35 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
23. Februar 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...